CCN3抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: P08430(CCN3 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P08430(CCN3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08430(CCN3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

CCN3 (Cellular Communication Network Factor 3), also known as Nephroblastoma Overexpressed (NOV), is a matricellular protein belonging to the CCN family (CCN1-6). It plays multifaceted roles in cellular processes such as proliferation, differentiation, adhesion, and extracellular matrix remodeling. CCN3 is implicated in various physiological and pathological conditions, including cancer, cardiovascular diseases, and bone metabolism. Its expression exhibits context-dependent duality, acting as either a tumor suppressor or promoter depending on tissue type and microenvironment.

CCN3 antibodies are essential tools for studying its biological functions and clinical relevance. They enable detection of CCN3 in techniques like Western blotting, immunohistochemistry, and ELISA. Due to CCN3's structural complexity (containing four conserved domains with multiple isoforms through alternative splicing), developing specific antibodies remains challenging. Current antibodies target distinct epitopes, with some recognizing conserved regions across species, while others detect specific isoforms. Recent research focuses on characterizing CCN3's role in disease mechanisms, particularly in tumor progression and tissue fibrosis, driving demand for reliable antibodies. Therapeutic applications are emerging, with antibodies being explored for targeting CCN3-mediated pathways in cancers and fibrotic disorders. Validation of antibody specificity continues to be critical for advancing both basic research and clinical translation.